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Objectives
• Describe US contrast agents
– How they differ from MR/CT agents
• Review safety/administration
• Highlight major applications
• Describe some future applications
Ultrasound Contrast Agents
• Earliest agitated saline (Gramiak, 1968)
• Short half-life, trapped by pulmonary 
capillaries
• Manufactured microbubbles from 2 – 7 
microns
• Smaller than RBC, so can pass through 
pulmonary circulation
Gramiak R, Shah PM. Echocardiography of 
the aortic root.
Invest Radiol 1968;3:356–66 
Quaia, E. Eur Radiol 2007; 17:1995-2008.
Microbubbles ex vivo
Definity (lipid shells) Optison (protein shell) against RBCs
Wilson SR , Burns PN  Microbubble-enhanced US in Body Imaging: What Role? Radiology 
2010, 257, 24-39. 
Chemical Content
• Microbubbles of gas in an encapsulating shell
• Air in a polysaccharide (Levovist)
• perflurocarbon or sulfur hexachloride stabilized 
by a thin shell (Definity, Lumason, Imagent-lipid) 
(Optison-protein)
• Most only intravascular
• Some drugs have hepatic (Levovist, Sonazoid) 
or splenic (Lumason) phase
Stewart and Sidhu; The British Journal of Radiology, 79 (2006), 188–194
Mode of Administration
• .5-2cc IV- bolus (preferred) or infusion
• Enhances blood signal 500-1000x
• Lasts 5 min (avg.) with bolus- longer with 
infusion. 
• Bubbles rupture, gas exhaled via lungs, shell 
metabolized by the body
• Major risk is anaphylaxis- at rate of 1/7000 
(U.S.) to 1/10,000 (Europe) less than that of 
CT, comparable to most antibiotics. 
Wilson SR , Burns PN  Microbubble-enhanced US in Body Imaging: What Role? Radiology 
2010, 257, 24-39. 
Is it Safe?
• U of R has administered >10,000 doses without a 
serious adverse event
• Definity does cause mild back pain-self limited- in 
1/200 patients.
• October 2007 FDA issued “black box” warning due to 
a few serious events (possible anaphylaxis)  
worldwide (4 deaths in the US) in patients having 
cardiac events- No cause and effect established
• Black Box modified 9 months later
Retrospective Results
• Kusnetsky reviews 18,671 hospitalized 
patients undergoing echocardiography
• No effect of contrast on mortality
• Patients receiveing CEUS exams did better 
than those who did not get agent
Kusnetzky LL , Khalid A , Khumri TM , Moe TG , Jones PG , Main ML . Acute 
mortality in hospitalized patients undergoing echocardiography with and without 
an ultrasound contrast agent: results in 18,671 consecutive studies . J Am Coll 
Cardiol 2008 ; 51 ( 17 ): 1704 – 1706 .
Current FDA recommendations
• Assess all patients for the presence of any 
condition precluding contrast administration 
(allergy)
• In patients with pulmonary hypertension or 
unstable cardiopulmonary conditions, monitor 
VS, ECG and O2sat for 30 minutes after 
Optison or Definity or Lumason
• Have resuscitation equipment available
US Contrast in Radiology
• Approved for Liver in UK, Canada, Europe and 
Japan since early 2000’s 
• 2016- Lumason approved for liver imaging in 
the US for lesion characterization. 
April 4, 2016 -- The long wait is over. The U.S. Food and Drug 
Administration (FDA) for the first time has approved the use of an 
ultrasound contrast agent for radiology applications, giving the nod to 
Lumason from Bracco Diagnostics to be used for focal liver lesions.
Lumason was known previously in the U.S. as SonoVue, and it received 
initial FDA approval in October 2014 for use in patients with suboptimal 
echocardiograms to opacify the left ventricular chamber and to improve the 
delineation of the left ventricular endocardial border. The agent is still 
offered by Bracco under the SonoVue brand outside of the U.S.
Current Contraindications
• Known allergy to US contrast
• Patients with right to left or bidirectional 
cardiac shunts
– Recent MI
– Severe Heart Failure
– Consider Cardiology Consult
• Not for intra-arterial injection
How do they work?
• Unlike blood cells (same size) which we do not 
see, we see US contrast because
– Bubbles contain gas which reflects the sound
– Bubbles oscillate in the 3-5MHz range (same as we 
use for abdominal US) creating echoes of their own, 
independent of those transmitted by the machine.
– These independent echoes are a multiple of the 
inciting frequency, and are known as harmonics
– We can selectively receive the harmonic frequency 
and see only the bubbles signal, suppressing 
background. 
Liver Imaging with Contrast
• Liver image (MIP) 11 
sec after injection.
• Note the number 
and small size of the 
vessels (down to 5th
order branches) seen 
only with contrast. 
• Deficit area is a 
hemangioma
Wilson SR , Burns PN  Microbubble-enhanced US in Body Imaging: What Role? Radiology 
2010, 257, 24-39. 
Liver Mass Characterization
• Benign lesions: Hemangioma, FNH, equivalent 
to CT or MR- prolonged delayed enhancement
• Adenoma has some overlap with HCC- soft 
washout
• Metastases and HCC equivalent to CT/MR
– Better for early wash-in and washout  due to high 
frame rate and long observation times (up to 20 
minutes)
– Difficulty with deep lesions, blind spots under 
diaphragm and behind ribs
Why does this work? 
• Liver has dual blood supply
– 30% from HA-arrives in  15-30 sec from injection
– 70% from PV-arrives 50-70sec from injection
• Malignant Tumors supplied by HA’s
– enhance more than background liver, in HAP
– In PV phase , background liver enhances more 
than the malignant tumor (early for mets and 
CholangioCa, later for HCC
• Benign tumors have HA supply but stay 
enhanced in PV phase
Wilson et AJR 2006
Figure 1: Schematic shows the typical enhancement patterns of common benign and malignant lesions in the cirrhotic liver. 
RN = regenerative nodule, DN = dysplastic nodule, AP = arterial phase, PVP = portal venous phase, LP = late phase.
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IMPACT:  HCC in DN or higher grade focus HCC within lower grade nodule
CEUS in the Kidney
• Solid Mass characterization- equivalent to CT 
for Clear cell RCC, and superior for Papillary  
(showed minimal flow better than CT)  (1)
• Bosniak II lesions seen with CEUS (31 patients, 
accuracy 74% by CT, 90% by US, US tended to 
upstage lesions (thicker septae)- (2)
(1)Tamai H, Takiguchi Y, Oka M, et al. Contrast-enhanced ultrasonography in the diagnosis of 
solid renal tumors. J Ultrasound Med 2005;24(12):1635–1640
(2)Park BK, Kim B, Kim SH, Ko K, Lee HM, Choi HY. Assessment of cystic renal masses based 
on Bosniak classification: comparison of CT and contrast-enhanced US. Eur J Radiol 
2007;61(2):310–314.
Wilson SR , Burns PN  Microbubble-enhanced US in Body Imaging: What Role? Radiology 
2010, 257, 24-39. 
Park BK, Kim B, Kim SH, Ko K, Lee HM, Choi HY. Assessment of cystic 
renal masses based on Bosniak classification: comparison of CT and 
contrast-enhanced US. Eur J Radiol 2007;61(2):310–314.
Number of Septae US >CT
Park BK, Kim B, Kim SH, Ko K, Lee HM, Choi HY. Assessment of cystic 
renal masses based on Bosniak classification: comparison of CT and 
contrast-enhanced US. Eur J Radiol 2007;61(2):310–314.
Prospective CEUS vs CT Complex Cysts
• 40 patients with complex cystic masses 
detected by CT
• 3 readers
• Path outcome or 24 mo F/U
• 21 RCCs, 9 complex cysts, 2MCNs, 8 simple 
cysts
• CEUS accuracy 80-83%, vs 63-75% CT
• Non-enhanced US accuracy only 30%
Quaia E, Bertolotto M, Cioffi V, et al. Comparison of Contrast-Enhanced Sonography with 
Unenhanced Sonography and Contrast-Enhanced CT in the Diagnosis of Malignancy in 
Complex Cystic Renal Masses AJR 2008; 191:1239-1249
Patient with Indeterminate Mass (MR) 
who cannot get CT or MR contrast
Patient with Indeterminate Mass on 
MR who cannot get CT or MR contrast
Pre Contrast Post Contrast
Patient with CRF suspected Mass on 
CT and unenhanced US. 
Patient with CRF suspected Mass on 
CT and unenhanced US. 
Patient with Indeterminate Mass on 
Contrast CT- 86 yo  female
US Contrast 2nd bolus combined phases
Vascular/Interventional
Applications
• Hepatic/Renal transplants- confirm vascular 
patency
• Endografts- diagnose leaks/monitor therapy
• Monitor ablations
IMPROVED HA VISUALIZATION 
WITH US CONTRAST
• 8/72  no flow on CDUS 
• 6  flow on CEUS 
(Optison .5ml)
– confirmed with angio or 
nl f/u US.
• 2 no flow, angiography 
confirmed
• US sensitivity rose from 
.91 to 1.0 (p<.014)
Benjamin K. Hom, BS, Ruchi Shrestha, MD, Suzanne L. Palmer, MD, Michael D. Katz, MD, R. 
Rick Selby, MD, Zhanna Asatryan, BA, Jabali K. Wells, BS and Edward G. Grant, MD Prospective 
Evaluation of Vascular Complications after Liver Transplantation: Comparison of 
Conventional and Microbubble Contrast-enhanced US Radiology 2006;241:267-274
AAA ENDOGRAFT SURVEILLANCE AND 
THERAPY: ROLE OF US
• CT preferred to assess graft anatomy, and to dx  stent 
migration, leaks
• CEUS equally effective to CT and DSA for endoleaks 
in small groups of selected patients: 20(a), 30(b) and 
24(c) but less effective in overall literature review (d)
• Occasionally better for delayed and/or small leaks
• US potentially useful to guide therapy
a) Bendick PJ. Bove PG. Long GW. Zelenock GB. Brown OW. Shanley CJ. Efficacy of ultrasound scan contrast agents in the noninvasive follow-up of aortic stent 
grafts. Journal of Vascular Surgery. 37(2):381-5, 2003 Feb.
b) Napoli V. Bargellini I. Sardella SG. Petruzzi P. Cioni R. Vignali C. Ferrari M. Bartolozzi C. Abdominal aortic aneurysm: contrast-enhanced US for missed endoleaks 
after endoluminal repair. Radiology. 233(1):217-25, 2004 Oct.
c) Dill-Macky MJ, Aortic Endografts: Detecting Endoleaks Using Contrast-enhanced Ultrasound. Ultrasound Quarterly. 22:49-52, 2006
d) Sun Z, Diagnostic value of color duplex ultrasonography in the follow-up of endovascular repair of abdominal aortic aneurysm. Journal of vascular and 
interventional radiology [1051-0443] 2006 vol:17 iss:5 pg:759 -64 
84 YO DIABETIC WITH ENDOGRAFT 
AORTIC REPAIR
endoleak AAA 5cm 
attempted 
angiographic rx.
8 mo later persistent 
endoleak AAA 
5.6cm 2 yrs later AAA 6.3cm  with 
renal insufficiency –angio same 
time shows no endoleak
Gray scale and color Doppler show AAA
Only contrast study shows endoleak
POST THROMBIN
After initial1000u thrombin injection the leak is no longer seen 
with repeat contrast bolus (Definity .75cc/bolus)
Contrast guided and monitored RFA of Renal Tumors
Copyright © 2013 Ultrasound Quarterly. 
Published by Lippincott Williams & Wilkins.
62
Contrast-Enhanced Ultrasound-
Guided Radiofrequency Ablation of 
Renal Tumors
Lackey, Logan II; Peterson, Cynthia; 
Barr, Richard G.
Ultrasound Quarterly. 28(4):269-
274, December 2012.
doi: 
10.1097/RUQ.0b013e318274de66
c/o Richard Barr
Other 
Applications
• Bowel (IBD, 
Ischemia)
• Cystoscopy
(VCUG)
• Trauma
• Ovary, 
Prostate?
CEUS in Crohn’s Disease Ripolles et al Insights Imaging Dec 2011
Conclusions
• US Contrast a powerful tool to enhance US diagnosis
• Primary use in characterizing focal lesions (liver-
Wilson et al)
• Useful in assessing ablation margins (Liver, kidney-
european studies)
• Vascular agent for intra-abdominal vessels 
(transplants, vascular stents)
• Applications in bowel (Wilson), ovary, prostate?
• Great potential use in patients who cannot receive 
CT or MR contrast due to allergy, renal function or 
location (interventional, OR, etc)
unknowns
63 yo with cirrhosis- HCC screen
Hepatitis C, GFR 30, pacemaker
• 1.7cm
• Internal flow
• Dx?

40 HU10-24 HU
67 F with lung carcinoid and 
Indeterminate mass left K 
67 F with lung carcinoid and 
Indeterminate mass left K, neg bx
21 HU 42 HU
